PRESS RELEASE:
-Company presents corporate update at investor forum –
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–October 19, 2015–
Xcovery, a developer of targeted therapeutics for cancer, today announced plans to present a company update, including preliminary clinical data from studies of X-396 for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), at the 14th Annual BIO Investor Forum in San Francisco on Wednesday, Oct. 21, 2015, at 3:00 p.m. PDT in the Davidson room Oncology track.
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.
About Xcovery
Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors. For more information, visit www.xcovery.com.
About X-396
X-396, a small molecule ALK inhibitor, is being investigated for the treatment of ALK+ NSCLC, lymphoma and neuroblastoma. X-396 has been validated in potency and selectivity assays that demonstrate it is more selective and up to 10 times more potent than competitive ALK inhibitors tested. X-396 has also shown activity in some ALK mutations that suggest resistance to other small molecule ALK inhibitors. X-396 is currently enrolling patients in a Phase II human clinical trial.
About Non-Small Cell Lung Cancer and ALK
Lung cancer is the second most common type of cancer identified in the United States with an estimated 221,000 new diagnoses expected in 2015. Non-small cell lung cancer is the most common type of lung cancer, accounting for an estimated 85-90% of the lung cancer cases.
The anaplastic lymphoma kinase (ALK) gene is located on chromosome 2 and rearrangement of the ALK gene can lead to its activation or expression therefore increasing a person’s chance of certain types of cancer, including NSCLC. Between three and seven percent of patients with NSCLC have the ALK rearrangement making this a molecular target warranting investigation for NSCLC patients.
Forward-Looking Statements
This press release contains forward-looking statements that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151019005834/en/
Corporate Contact:
Xcovery
Teri Swift, 561-406-9705
teri@xcovery.com
or
Media Contact:
LaVoie Health Science
David Connolly, 617-374-8800 ext. 108
dconnolly@lavoiehealthscience.com